

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CR Group L.P.</u>  (Last) (First) (Middle) 1000 MAIN ST. SUITE 2500  (Street) HOUSTON TX 77002  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Zyla Life Sciences [ ZCOR ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/20/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/20/2020		D <sup>(1)</sup>		4,586,874	D	\$0.00 <sup>(1)</sup>	0	I	By Loan Security Holdings I LLC <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Warrants	\$0.0001	05/20/2020		D <sup>(3)</sup>			2,436,459	(3)	(3)	Common Stock	2,436,459	(3)	0	I	By Loan Security Holdings I LLC <sup>(2)</sup>

1. Name and Address of Reporting Person\*  
CR Group L.P.  
 (Last) (First) (Middle)  
 1000 MAIN ST.  
 SUITE 2500  
 (Street)  
 HOUSTON TX 77002  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
CRG Partners III - Parallel Fund B (Cayman) L.P.  
 (Last) (First) (Middle)  
 1000 MAIN ST.  
 SUITE 2500  
 (Street)  
 HOUSTON TX 77002  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
CRG Partners III - Parallel Fund (A) L.P.  
 (Last) (First) (Middle)  
 1000 MAIN ST.  
 SUITE 2500  
 (Street)

HOUSTON	TX	77002
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">CRG Partners III (Cayman) Lev AIV I L.P.</a>		
(Last)	(First)	(Middle)
1000 MAIN ST. SUITE 2500		
(Street)		
HOUSTON	TX	77002
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">CRG Partners III (Cayman) Unlev AIV I L.P.</a>		
(Last)	(First)	(Middle)
1000 MAIN ST. SUITE 2500		
(Street)		
HOUSTON	TX	77002
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">CRG Partners III L.P.</a>		
(Last)	(First)	(Middle)
1000 MAIN ST. SUITE 2500		
(Street)		
HOUSTON	TX	77002
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Loan Security Holdings I LLC</a>		
(Last)	(First)	(Middle)
1000 MAIN ST. SUITE 2500		
(Street)		
HOUSTON	TX	77002
(City)	(State)	(Zip)

**Explanation of Responses:**

- Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 16, 2020, by and among the Issuer and Asserzio Therapeutics, Inc., a Delaware corporation, Asserzio Holdings, Inc., a Delaware corporation ("Parent"), Zebra Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent and Alligator Merger Sub, Inc., a Delaware corporation, whereby each share of Issuer common stock was cancelled and converted into the right to receive 2.5 shares of Parent common stock having a market value of \$0.80 per share, the closing price on the day prior to the effective date of the merger, as provided in the Merger Agreement.
- The securities are held by Loan Security Holdings I LLC, a wholly owned LLC held by CRG Partners III - Parallel Fund "A" LP, CRG Partners III - Parallel Fund "B" (Cayman) L.P., CRG Partners III (Cayman) Lev AIV I L.P., CRG Partners III (Cayman) Unlev AIV I L.P., and CRG Partners III L.P. (collectively, the "CRG Entities"). CRG Entities collectively hold all of the issued and outstanding shares of Loan Security Holdings I LLC. CR Group L.P. may be deemed to beneficially own the shares and the warrants by virtue of its position as the investment manager for the CRG Entities.
- Disposed of pursuant to the Merger Agreement in exchange for a warrant to acquire 6,091,148 shares of Parent common stock at an exercise price of \$0.0004 per share.

**Remarks:**

/s/ Nathan D. Hukill, authorized signatory for CR Group L.P. and 05/22/2020 each of the CRG Entities  
/s/ Andrei Dorenbaum, authorized signatory for Loan Security Holdings I LLC 05/22/2020  
 \*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**